Then, the patient was observed for CR of the tumor after receiving one cycle of therapy with ipilimumab and nivolumab combination.16 At present, several clinical trials combining PD-1/PD-L1 inhibitors and anti-CTLA-4 therapy are under way (NCT03668119, NCT04323046, NCT04416568, NCT04465643, NCT04495010, NCT04500548, NCT02693535, NCT03837899, and NCT04480502) (online supplemental table 5). This evidence concerns the gene CD274 and neoplasm.